These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 456593)

  • 1. Platelet antiheparin proteins and antithrombin III interact with different binding sites on heparin molecule.
    Niewiarowski S; Rucinski B; James P; Lindahl U
    FEBS Lett; 1979 Jun; 102(1):75-8. PubMed ID: 456593
    [No Abstract]   [Full Text] [Related]  

  • 2. Two-dimensional affinity resolution electrophoresis demonstrates that three distinct heparin populations interact with antithrombin III.
    Edens RE; Fromm JR; Fromm SJ; Linhardt RJ; Weiler JM
    Biochemistry; 1995 Feb; 34(8):2400-7. PubMed ID: 7873519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of heparin binding to antithrombin III by crossed immunoelectrophoresis.
    Barrowcliffe TW
    Thromb Haemost; 1980 Feb; 42(5):1434-45. PubMed ID: 7368150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pasteurisation induced changes in an antithrombin III concentrate.
    Winkelman L; Haddon ME
    Thromb Res; 1986 Jul; 43(2):219-27. PubMed ID: 3738862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the antithrombin-binding site in heparin.
    Lindahl U; Bäckström G; Höök M; Thunberg L; Fransson LA; Linker A
    Proc Natl Acad Sci U S A; 1979 Jul; 76(7):3198-202. PubMed ID: 226960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric distribution of sites with high affinity for antithrombin III in rat skin heparin proteoglycans.
    Horner AA; Young E
    J Biol Chem; 1982 Aug; 257(15):8749-54. PubMed ID: 7096332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulant properties of heparin preparations from different animal sources with equivalent high affinity for antithrombin III.
    Nagasawa K; Uchiyama H
    J Biochem; 1984 Mar; 95(3):619-26. PubMed ID: 6725227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of molecular weight on heparin binding to platelets.
    Horne MK; Chao ES
    Br J Haematol; 1990 Mar; 74(3):306-12. PubMed ID: 2334638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of heparin and heparin fractions on platelet aggregation.
    Salzman EW; Rosenberg RD; Smith MH; Lindon JN; Favreau L
    J Clin Invest; 1980 Jan; 65(1):64-73. PubMed ID: 6243142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of monosaccharide residues in heparin binding to antithrombin III.
    Atha DH; Lormeau JC; Petitou M; Rosenberg RD; Choay J
    Biochemistry; 1985 Nov; 24(23):6723-9. PubMed ID: 4084555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic analysis of various heparin fractions and heparin substitutes in the thrombin inhibition reaction.
    Pletcher CH; Cunningham M; Nelsestuen GL
    Biochim Biophys Acta; 1985 Jan; 838(1):106-13. PubMed ID: 2578296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin III, a serpin family protease inhibitor, is a major heparin binding protein in porcine aqueous humor.
    Rao PV; Allingham RR; Herndon LW; Epstein DL
    Biochem Biophys Res Commun; 2000 May; 272(1):1-5. PubMed ID: 10872794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 14. Conditions for radioiodination of antithrombin III retaining its biological properties.
    Caix J; Perrot Minnot A; Beziade A; Vuillemin L; Belloc F; Baquey C; Ducassou D
    Int J Rad Appl Instrum A; 1987; 38(12):1003-6. PubMed ID: 2828272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of rat skin heparin chains with high affinity for antithrombin.
    Horner AA
    Biochem J; 1987 Jun; 244(3):693-8. PubMed ID: 3446185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J; Ofosu F; Buchanan M
    Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Separation of antithrombin III variants by micellar electrokinetic chromatography.
    Dönges R; Römisch J; Stauss H; Brazel D
    J Chromatogr A; 2001 Jul; 924(1-2):307-13. PubMed ID: 11521878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin binding and protease inhibitor activity of chemically modified antithrombin III.
    Blackburn MN; Smith RL; Sibley CC; Johnson VA
    Ann N Y Acad Sci; 1981; 370():700-7. PubMed ID: 6791550
    [No Abstract]   [Full Text] [Related]  

  • 19. Dansyl (5-dimethylaminonaphthalene-1-sulphonyl)-heparin binds antithrombin III and platelet factor 4 at separate sites.
    Piepkorn MW
    Biochem J; 1981 May; 196(2):649-51. PubMed ID: 7317004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction between heparin and antithrombin III: a comparison of two different heparin-dye conjugates.
    Jones GR; Hashim R; Power DM
    Biochim Biophys Acta; 1987 Jul; 925(1):57-62. PubMed ID: 3109497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.